Results 71 to 80 of about 2,864 (172)

Evaluation of a short, all oral treatment regimen including bedaquiline, delamanid, linezolid, clofazimine, and pyrazinamide named “Regimen C” for pre-XDR tuberculosis in Niger

Frontiers in Tuberculosis
BackgroundThe emergence of extensively drug-resistant tuberculosis (XDR-TB) poses a serious challenge to global tuberculosis control, particularly in high-burden countries like Niger. In 2021, a new fully oral, shorter treatment regimen, named regimen C,
Soumana Boubacar Soumana, Abdourahamane Yacouba, Abdourahamane Yacouba, Cheikh Aboubacar Abdoul Lawi, Ibrahim Oumar, Bassirou Souleymane, Alphazazi Soumana, Tapha Ounoussa, Mahamadou Doutchi, Mamane Daou, Souleymane Brah, Souleymane Brah, Eric Adehossi, Saidou Mamadou, Saidou Mamadou   +14 more
doaj   +1 more source

Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis

Pharmaceuticals
Mycobacterium tuberculosis infections continue to pose a significant global health challenge, particularly due to the rise of multidrug-resistant strains, random mycobacterial mutations, and the complications associated with short-term antibiotic ...
Ahmad Diab, Henry Dickerson, Othman Al Musaimi   +2 more
doaj   +1 more source

Effectiveness of new antituberculosis drugs in the treatment of children and adolescents with chemoresistant tuberculosis

Infusion & Chemotherapy
BACKGROUND. There is a significant decrease the effectiveness of antituberculous (anti-TB) treatment on the background of multidrug and extensive drug resistance (MDR/XDR) of Mycobacterium tuberculosis.
M.І. Sakhelashvili, I.L. Рlatonova, O.I. Sakhelashvili-Вil   +2 more
doaj   +1 more source

Global child-friendly anti-TB medicines – where do we stand?

IJTLD Open
SUMMARY: An increasing number of children are diagnosed and started on antituberculosis treatment. Despite progress in developing child-friendly antituberculosis formulations for drug-susceptible and drug-resistant TB, a single-medicine rifampicin ...
H.S. Schaaf, D.T. Wademan, L.E. van der Laan   +2 more
doaj   +1 more source

Bedaquiline plus delamanid for XDR tuberculosis [PDF]

The Lancet Infectious Diseases, 2016
Marie, Lachâtre, Christophe, Rioux, Damien, Le Dû, Mathilde, Fréchet-Jachym, Nicolas, Veziris, Elisabeth, Bouvet, Yazdan, Yazdanpanah   +6 more
openaire   +2 more sources

Cost-effectiveness evaluation of bedaquiline- and delamanid-containing regimens for multidrug-/rifampicin-resistant tuberculosis in China: a retrospective study based on three nationwide, real-world multicenter cohorts. [PDF]

J Thorac Dis
Sun D, Li Z, Qiu Y, Shu W, Zhang L, Gao J, Liu Y.   +6 more
europepmc   +1 more source

Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model. [PDF]

Antimicrob Agents Chemother
Cummings JE, Woolhiser LK, Guglielmi V, Romano A, Pauly S, Zimmerman M, Kaya F, Walter ND, Robertson GT, Slayden RA.   +9 more
europepmc   +1 more source

A Comprehensive Approach to Selection of Adverse Drug Reactions for a Drug with Conditional Marketing Authorisation in the European Union. [PDF]

Adv Ther
Hittel N, Lazarevic N, Martin A, Schorn B, Leporowski A, Zhang V, George V, van Heumen E.   +7 more
europepmc   +1 more source

Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa. [PDF]

Clin Infect Dis
Loveday M, Clarence E, Hlangu S, Singh N, Chotoo S, Brust JCM, Waitt C, Court R, Furin J.   +8 more
europepmc   +1 more source

Incidence and risk factors of adverse drug reactions in multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) regimens containing new drugs: a retrospective study of two national multicenter cohorts. [PDF]

J Thorac Dis
Wang Y, Fu L, Li Z, Liu Y, Li L.
europepmc   +1 more source